Granisetron News and Research

RSS
Granisetron is the active ingredient in a drug used to treat nausea and vomiting caused by cancer treatment. Granisetron is a type of serotonin receptor antagonist and a type of antiemetic.
Health Canada approves BDSI's NDS for ONSOLIS

Health Canada approves BDSI's NDS for ONSOLIS

BDSI Sciences to purchase $10M of securities in registered direct offering

BDSI Sciences to purchase $10M of securities in registered direct offering

Contura submits PMA for Aquamid

Contura submits PMA for Aquamid

FDA approves Sagent Pharmaceuticals' two ANDAs to market granisetron

FDA approves Sagent Pharmaceuticals' two ANDAs to market granisetron

BEMA Granisetron development program: BDSI announces positive meeting with FDA

BEMA Granisetron development program: BDSI announces positive meeting with FDA

BioDelivery Sciences International announces filing of Annual Report with U.S. SEC

BioDelivery Sciences International announces filing of Annual Report with U.S. SEC

A.P. Pharma's NDA for APF530 in prevention of CINV: FDA issues Complete Response Letter

A.P. Pharma's NDA for APF530 in prevention of CINV: FDA issues Complete Response Letter

A.P. Pharma reports net loss of $1.9M for fourth-quarter of 2009

A.P. Pharma reports net loss of $1.9M for fourth-quarter of 2009

China Pharma Holdings reports 21% increase in 2009 revenue

China Pharma Holdings reports 21% increase in 2009 revenue

Solasia Pharma K.K. signs License and Supply Agreement with Kyowa Hakko Kirin to market SP-01

Solasia Pharma K.K. signs License and Supply Agreement with Kyowa Hakko Kirin to market SP-01

BDSI provides update on product portfolio, key upcoming milestones

BDSI provides update on product portfolio, key upcoming milestones

BDSI to discuss planned BEMA Granisetron IND with the FDA

BDSI to discuss planned BEMA Granisetron IND with the FDA

Almac Discovery initiates Phase I clinical trial of intranasal Granisetron for CINV

Almac Discovery initiates Phase I clinical trial of intranasal Granisetron for CINV

A.P. Pharma announces financial results for its third quarter ended September 30, 2009

A.P. Pharma announces financial results for its third quarter ended September 30, 2009

Solasia Pharma completes Phase I clinical trial for Sancuso extended release transdermal granisetron patch

Solasia Pharma completes Phase I clinical trial for Sancuso extended release transdermal granisetron patch

A.P. Pharma to raise funds through placement

A.P. Pharma to raise funds through placement

A.P. Pharma submits NDA for APF530 in chemo-induced nausea and vomiting

A.P. Pharma submits NDA for APF530 in chemo-induced nausea and vomiting

Barr receives approval for generic KYTRIL tablets

Barr receives approval for generic KYTRIL tablets

Subcutaneous administration of an antiemetic for treating vomiting caused by chemotherapy

Subcutaneous administration of an antiemetic for treating vomiting caused by chemotherapy

Drugs given to stop nausea and vomiting after surgery help only a few people

Drugs given to stop nausea and vomiting after surgery help only a few people